about
Identification of seven new prostate cancer susceptibility loci through a genome-wide association studySeven prostate cancer susceptibility loci identified by a multi-stage genome-wide association studyIdentification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.Clinical utility of diffusion-weighted magnetic resonance imaging in prostate cancer.Stereotactic body radiotherapy for oligometastases.Development of UK guidance on the management of erectile dysfunction resulting from radical radiotherapy and androgen deprivation therapy for prostate cancer.Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder.A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease.Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancerActive surveillance with selective radical treatment for localized prostate cancer.Reducing treatment toxicities in the management of good prognosis testicular germ cell tumors.A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact.Biological dose escalation and hypofractionation: what is there to be gained and how will it best be done?Is biochemical relapse-free survival after profoundly hypofractionated radiotherapy consistent with current radiobiological models?Stereotactic body radiotherapy for prostate cancer.Initial UK Experience of Stereotactic Body Radiotherapy for Extracranial Oligometastases: Can We Change the Therapeutic Paradigm?Diffusion-weighted magnetic resonance imaging for monitoring prostate cancer progression in patients managed by active surveillance.Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer.Reply: 'Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'.Prostate stereotactic body radiotherapy with simultaneous integrated boost: which is the best planning method?Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance.New horizons and hurdles for UK radiotherapy: can prostate stereotactic body radiotherapy show the way?Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer.Intensity modulated radiation therapy allows prostate and dose-escalated pelvic radical radiation therapy after renal transplantationProstate Stereotactic Body Radiotherapy — First UK ExperienceThe Efficacy of Preventing Neutropenic Sepsis in Patients with Testicular Germ Cell Tumours: Results of Two Consecutive AuditsA Study of Diffusion-Weighted Magnetic Resonance Imaging in Men with Untreated Localised Prostate Cancer on Active SurveillanceProstate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling timeTreating IIA/B Seminoma With Combination Carboplatin and RadiotherapyCorrelation of diffusion-weighted MRI with whole mount radical prostatectomy specimensComplete resolution of anal cancer after chemotherapy for acute myeloid leukaemia
P50
Q29417022-2A9B6C84-9D0C-4D3F-8093-2F357241FFAFQ29417074-75D26C79-04B6-4B68-8FED-95A663485C7CQ29417155-EFCC952C-2AD1-470E-8B36-4BF1E876CD65Q33919001-FC1A4951-F090-464C-969D-17AD0E7482A8Q34320125-DB8C3FDD-C6E9-4812-91B2-2799DED85D0FQ35022939-B32D994E-BD41-46B7-8B8D-28C6662F99E8Q35572535-83359DE9-C487-409D-B8B6-5BEE8A3B7655Q35603639-ECB6778C-35AC-4C04-AAE4-A5BCDD63D970Q36477652-3E84D507-A73F-4286-B925-4FDA72DB8DA3Q36928846-50A01B8B-085E-4902-A8A2-6F184B54B8E0Q36964046-08CEEBCA-1CCA-4D9F-A6CF-14242C7C29EDQ37385388-C6012413-F503-4BE7-9B82-936302ED753AQ37632049-90523E35-D878-425C-80B9-7801CB1B4E39Q38117984-47A9D6BE-F001-4CFC-AC2A-47D1B3722999Q38188223-44FCD491-EF2A-423F-B848-9284D776B66CQ38364454-AFB911F8-4256-49AF-91EE-CF7DFA7520FCQ38442205-72426129-25D0-4666-80C5-31483F341BD2Q42419373-0D975680-A3D3-4396-9516-E5ACF5AE647BQ42641870-277B4491-1119-4829-B5BF-EA2080CFFEB3Q42748594-2A429A05-4375-4961-860E-01A7449ED20FQ42841450-813D44F4-502D-4925-8A2E-11BB7C377262Q43502197-DD84B5CA-77C1-469F-8160-EAD7A5A64200Q43591082-A8A33BA6-CE43-400B-B3A3-16E296D68352Q46539252-874F8E05-88D7-4751-8E7C-534B07560D9CQ63966736-6C4CA71D-4272-4CE7-802F-B7837CF50C26Q63966737-203D3D8D-2958-488F-9733-DEBC4A2A9A63Q63966738-793C244F-77EE-42A0-9BD0-B162170CBE2FQ63966739-CD1D6539-AC96-458E-B35B-BBA7B86FBA03Q63966740-D6F2EBFA-2326-46F0-9508-0B90E352296DQ63966741-EDFBB10F-E367-484B-9C08-228D65DF15E6Q63966742-36BF519C-C5BC-4A54-886C-3014AB7ABCD0Q63966743-9074AE8E-8773-4FAC-A610-5F5BAD288AE7
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Nicholas Van As
@ast
Nicholas Van As
@en
Nicholas Van As
@es
Nicholas Van As
@nl
Nicholas Van As
@sl
type
label
Nicholas Van As
@ast
Nicholas Van As
@en
Nicholas Van As
@es
Nicholas Van As
@nl
Nicholas Van As
@sl
prefLabel
Nicholas Van As
@ast
Nicholas Van As
@en
Nicholas Van As
@es
Nicholas Van As
@nl
Nicholas Van As
@sl
P106
P21
P31
P496
0000-0001-6829-8788